BioSpace News Archive

TheracosBio today announced the appointment of Brian Connelly as President and Chief Executive Officer.

Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, reported financial results for the three months ended June 30, 2023.

Y-mAbs Therapeutics, Inc. announced that it will report its financial results for the second quarter ended June 30, 2023, on Thursday, August 10, 2023, after the close of the U.S. financial markets.

Sanara MedTech Inc., a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced details for the release of its results for the quarter ended June 30, 2023.

MiMedx Group, Inc., announced operating and financial results for the second quarter 2023, which ended June 30, 2023, including net sales of $81.3 million, net income of $1.2 million and Adjusted EBITDA1 of $14.1 million.

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, announced the closing of its underwritten public offering of 14,375,000 shares of its common stock at a price of $4.80 per share.

PROCEPT BioRobotics® Corporation announced the commencement of an underwritten public offering of $125,000,000 of shares of its common stock.

Beyond Air, Inc. announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will present a corporate overview and participate in one-on-one meetings at BTIG’s Virtual Biotechnology Conference, on Monday, August 7, 2023.

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, announced the closing of its public offering of 7,000,000 shares of its common stock and warrants to purchase up to an aggregate of 7,000,000 shares of common stock in a public offering at a combined offering price of $1.00 per share and accompanying warrant.

Amgen announced that its Board of Directors declared a $2.13 per share dividend for the third quarter of 2023.